Freiburg ZNS-NHL Study

Primary Non Hodgkin Lymphoma of the Central Nervous System Clinical Trial

Official title: Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine whether combined chemotherapy [rituximab plus high dosage methotrexate (max. 2 cycles) followed by arabinoside/thiotepa (max. 2 cycles) followed by high dosage carmustin/thiotepa] followed by peripheral blood stem cell transplantation is effective in the treatment of cerebral Non Hodgkin lymphoma [PCNSL].

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma, Non-Hodgkin
• Primary Non Hodgkin Lymphoma of the Central Nervous System

• NCT number: NCT00647049
• Study type: Interventional
• Source: University Hospital Freiburg
• Contact: Gerald Illerhaus, Dr.
• Phone: 00497612703785
• Email: Gerald.Illerhaus@uniklinik-freiburg.de
• Status: Recruiting
• Phase: Phase 2
• Start date: January 2007
• Completion date: August 2013